The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

A report on the FDA PREPP initiative’s work in 2020 aims to strengthen the Agency’s response to future public health emergencies. 

FDA Publishes COVID-19 Pandemic Recovery and Preparedness Plan Summary Report 

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Packaging and transporting large quantities of COVID-19 vaccines pose challenges for the cold chain.

Accelerating Technology Adoption to Track the Cold Chain

Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany facility to prepare Novavax’s COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.

Baxter and Novavax Enter into COVID-19 Vaccine Sterile Manufacturing Agreement

The company plans to expand its global production capacity across six existing manufacturing facilities in Europe and the United States, as well as a new manufacturing facility in the US.

Pall to Invest $114 Million to Expand its Global Production Capacity

The company plans to deliver initial doses by mid-2021, and Australia will have the option to purchase up to 10 million additional doses through the agreement. 

Novavax Enters into Agreement with the Commonwealth of Australia for 51 Million Doses of its COVID-19 Vaccine

Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.

Bayer and CureVac to Collaborate on COVID-19 Vaccine Candidate

The European Commission has granted a conditional marketing authorization to Moderna for its COVID-19 vaccine.

EC Authorizes Moderna’s COVID-19 Vaccine for European Roll-Out

Amid pressure to get more vaccines administered faster, FDA pushes back against changes in dosing regimens.

FDA: Stick with Approved EUAs for COVID-19 Vaccines

The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States. 

Moderna and Recipharm Announce COVID-19 Vaccine Supply Agreement 

Part of Operation Warp Speed, the trial will enroll 30,000 people ages 18 to 64 and 65 and older at 115 sites.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success